Download PDF
Semin Reprod Med 2020; 38(02/03): 168-178
DOI: 10.1055/s-0040-1718741
Review Article

Animal Models of Adenomyosis

Ryan M. Marquardt
1   Department of Obstetrics, Gynecology and Reproductive Biology, Michigan State University, Grand Rapids, Michigan
2   Cell and Molecular Biology Program, Michigan State University, East Lansing, Michigan
,
Jae-Wook Jeong 
1   Department of Obstetrics, Gynecology and Reproductive Biology, Michigan State University, Grand Rapids, Michigan
,
Asgerally T. Fazleabas
1   Department of Obstetrics, Gynecology and Reproductive Biology, Michigan State University, Grand Rapids, Michigan
› Author Affiliations Funding Research reported in this publication was supported in part by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health under award number R01HD084478 to J.W.J. and T32HD087166 to R.M.M, MSU AgBio Research, and Michigan State University. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
› Further Information
    Permissions and Reprints

Abstract

Adenomyosis is a nonmalignant uterine disorder in which endometrial tissue exists within and grows into the myometrium. Animal models have generated limited insight into the still-unclear pathogenesis of adenomyosis, provided a platform for preclinical screening of many drugs and compounds with potential as therapeutics, and elucidated mechanisms underlying the pain and fertility issues that occur in many women with the disease. Spontaneous adenomyosis has been studied in nonhuman primates, primarily in the form of case reports. Adenomyosis is routinely experimentally induced in mice through methods such as neonatal tamoxifen exposure, pituitary engraftment, and human tissue xenotransplantation. Several studies have also reported hormonal or environmental toxicant exposures that give rise to murine adenomyosis, and genetically engineered models have been created that recapitulate the human-like condition, most notably involving alteration of β-catenin expression. This review describes the animal models for adenomyosis and their contributions to our understanding of the factors underpinning the development of symptoms. Animal models represent a unique opportunity for understanding the molecular basis of adenomyosis and developing efficacious treatment options for affected women. Herein, we assess their different potentials and limitations with regard to identification of new therapeutic interventions and reflect on future directions for research and drug validation.

Keywords

adenomyosis - animal model - infertility - nonhuman primates - rodents


Publication History

Article published online:
26 October 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Yen CF, Huang SJ, Lee CL, Wang HS, Liao SK. Molecular characteristics of the endometrium in uterine adenomyosis and its biochemical microenvironment. Reprod Sci 2017; 24 (10) 1346-1361
    CrossrefPubMedGoogle Scholar
  • 2 Aleksandrovych V, Basta P, Gil K. Current facts constituting an understanding of the nature of adenomyosis. Adv Clin Exp Med 2019; 28 (06) 839-846
    CrossrefPubMedGoogle Scholar
  • 3 Levgur M. Therapeutic options for adenomyosis: a review. Arch Gynecol Obstet 2007; 276 (01) 1-15
    CrossrefPubMedGoogle Scholar
  • 4 Koike N, Tsunemi T, Uekuri C. et al. Pathogenesis and malignant transformation of adenomyosis. (review) Oncol Rep 2013; 29 (03) 861-867
    CrossrefPubMedGoogle Scholar
  • 5 Maier V, Holl M, Dietze R. et al. Adenomyotic glands are highly related to endometrial glands. Reprod Biomed Online 2020; 40 (06) 769-778
    CrossrefPubMedGoogle Scholar
  • 6 Dior UP, Nisbet D, Fung JN. et al. The association of sonographic evidence of adenomyosis with severe endometriosis and gene expression in eutopic endometrium. J Minim Invasive Gynecol 2019; 26 (05) 941-948
    CrossrefPubMedGoogle Scholar
  • 7 Hever A, Roth RB, Hevezi PA. et al. Molecular characterization of human adenomyosis. Mol Hum Reprod 2006; 12 (12) 737-748
    CrossrefPubMedGoogle Scholar
  • 8 Habiba M. The animal model of adenomyosis. In: Uterine Adenomyosis. Springer; 2016: 123-127
    CrossrefGoogle Scholar
  • 9 Greaves P, White IN. Experimental adenomyosis. Best Pract Res Clin Obstet Gynaecol 2006; 20 (04) 503-510
    CrossrefPubMedGoogle Scholar
  • 10 Barrier BF, Allison J, Hubbard GB, Dick Jr EJ, Brasky KM, Schust DJ. Spontaneous adenomyosis in the chimpanzee (Pan troglodytes): a first report and review of the primate literature: case report. Hum Reprod 2007; 22 (06) 1714-1717
    CrossrefPubMedGoogle Scholar
  • 11 Graham KJ, Hulst FA, Vogelnest L, Fraser IS, Shilton CM. Uterine adenomyosis in an orang-utan (Pongo abelii/pygmaeus). Aust Vet J 2009; 87 (01) 66-69
    CrossrefPubMedGoogle Scholar
  • 12 Barrier BF, Malinowski MJ, Dick Jr EJ, Hubbard GB, Bates GW. Adenomyosis in the baboon is associated with primary infertility. Fertil Steril 2004; 82 (Suppl. 03) 1091-1094
    CrossrefPubMedGoogle Scholar
  • 13 DiGiacomo RF. Gynecologic pathology in the rhesus monkey (Macaca mulatta). II. Findings in laboratory and free-ranging monkeys. Vet Pathol 1977; 14 (06) 539-546
    CrossrefPubMedGoogle Scholar
  • 14 Baskin GB, Smith SM, Marx PA. Endometrial hyperplasia, polyps, and adenomyosis associated with unopposed estrogen in rhesus monkeys (Macaca mulatta). Vet Pathol 2002; 39 (05) 572-575
    CrossrefPubMedGoogle Scholar
  • 15 Vannuccini S, Petraglia F. Recent advances in understanding and managing adenomyosis. F1000 Res 2019; 8: 8
    Google Scholar
  • 16 Carrarelli P, Yen CF, Funghi L. et al. Expression of inflammatory and neurogenic mediators in adenomyosis. Reprod Sci 2017; 24 (03) 369-375
    CrossrefPubMedGoogle Scholar
  • 17 Vannuccini S, Tosti C, Carmona F. et al. Pathogenesis of adenomyosis: an update on molecular mechanisms. Reprod Biomed Online 2017; 35 (05) 592-601
    CrossrefPubMedGoogle Scholar
  • 18 Braundmeier AG, Fazleabas AT. The non-human primate model of endometriosis: research and implications for fecundity. Mol Hum Reprod 2009; 15 (10) 577-586
    CrossrefPubMedGoogle Scholar
  • 19 D'Hooghe TM, Kyama CM, Chai D. et al. Nonhuman primate models for translational research in endometriosis. Reprod Sci 2009; 16 (02) 152-161
    CrossrefPubMedGoogle Scholar
  • 20 Fazleabas AT. Progesterone resistance in a baboon model of endometriosis. Semin Reprod Med 2010; 28 (01) 75-80
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Hastings JM, Fazleabas AT. A baboon model for endometriosis: implications for fertility. Reprod Biol Endocrinol 2006; 4 (Suppl. 01) S7
    CrossrefPubMedGoogle Scholar
  • 22 Moses AS, Taratula OR, Lee H. et al. Nanoparticle-based platform for activatable fluorescence imaging and photothermal ablation of endometriosis. Small 2020; 16 (18) e1906936
    CrossrefPubMedGoogle Scholar
  • 23 Slayden OD. Translational in vivo models for women's health: the nonhuman primate endometrium--a predictive model for assessing steroid receptor modulators. Handb Exp Pharmacol 2016; 232: 191-202
    CrossrefPubMedGoogle Scholar
  • 24 Fazleabas AT, Brudney A, Gurates B, Chai D, Bulun S. A modified baboon model for endometriosis. Ann N Y Acad Sci 2002; 955: 308-317 , discussion 340–342, 396–406
    CrossrefPubMedGoogle Scholar
  • 25 Waterton JC, Breen SA, Dukes M, Horrocks M, Wadsworth PF. A case of adenomyosis in a pigtailed monkey diagnosed by magnetic resonance imaging and treated with the novel pure antiestrogen, ICI 182,780. Lab Anim Sci 1993; 43 (03) 247-251
    PubMedGoogle Scholar
  • 26 Oh SJ, Shin JH, Kim TH. et al. β-Catenin activation contributes to the pathogenesis of adenomyosis through epithelial-mesenchymal transition. J Pathol 2013; 231 (02) 210-222
    CrossrefPubMedGoogle Scholar
  • 27 Bellessort B, Bachelot A, Heude É. et al. Role of Foxl2 in uterine maturation and function. Hum Mol Genet 2015; 24 (11) 3092-3103
    CrossrefPubMedGoogle Scholar
  • 28 Gonzalez G, Behringer RR. Dicer is required for female reproductive tract development and fertility in the mouse. Mol Reprod Dev 2009; 76 (07) 678-688
    CrossrefPubMedGoogle Scholar
  • 29 Nagasawa H, Kusakawa S. Relationship between incidence and onset age of mammary tumours and uterine adenomyosis in four strains of mice: comparison with the findings of 40 generations previously. In Vivo 2001; 15 (04) 345-349
    PubMedGoogle Scholar
  • 30 Kida H. [Histological analysis of spontaneous adenomyosis-like changes in recombinant inbred mouse uterus (SMXA mouse)--a novel animal model for adenomyosis]. Nippon Sanka Fujinka Gakkai Zasshi 1994; 46 (04) 323-330
    PubMedGoogle Scholar
  • 31 Nagasawa H, Naito T. Enhanced potentials for mammary tumourigenesis and uterine adenomyosis in (SLN x C3H/He)F1 virgin mice. Lab Anim 1992; 26 (01) 23-24
    CrossrefPubMedGoogle Scholar
  • 32 Nagasawa H, Mori T. Stimulation of mammary tumorigenesis and suppression of uterine adenomyosis by temporary inhibition of pituitary prolactin secretion during youth in mice (41492). Proc Soc Exp Biol Med 1982; 171 (02) 164-167
    CrossrefPubMedGoogle Scholar
  • 33 Mori T, Nagasawa H, Takahashi S. The induction of adenomyosis in mice by intrauterine pituitary isografts. Life Sci 1981; 29 (12) 1277-1282
    CrossrefPubMedGoogle Scholar
  • 34 Walker BE. Ovariectomy of adult mice exposed prenatally to diethylstilbestrol. Cancer Lett 1987; 34 (02) 115-120
    CrossrefPubMedGoogle Scholar
  • 35 Koike E, Yasuda Y, Shiota M. et al. Exposure to ethinyl estradiol prenatally and/or after sexual maturity induces endometriotic and precancerous lesions in uteri and ovaries of mice. Congenit Anom (Kyoto) 2013; 53 (01) 9-17
    CrossrefPubMedGoogle Scholar
  • 36 Parrott E, Butterworth M, Green A, White IN, Greaves P. Adenomyosis--a result of disordered stromal differentiation. Am J Pathol 2001; 159 (02) 623-630
    CrossrefPubMedGoogle Scholar
  • 37 Tanwar PS, Lee HJ, Zhang L. et al. Constitutive activation of Beta-catenin in uterine stroma and smooth muscle leads to the development of mesenchymal tumors in mice. Biol Reprod 2009; 81 (03) 545-552
    CrossrefPubMedGoogle Scholar
  • 38 Huang TS, Chen YJ, Chou TY. et al. Oestrogen-induced angiogenesis promotes adenomyosis by activating the Slug-VEGF axis in endometrial epithelial cells. J Cell Mol Med 2014; 18 (07) 1358-1371
    CrossrefPubMedGoogle Scholar
  • 39 Suzuki-Kakisaka H, Murakami T, Hirano T, Terada Y, Yaegashi N, Okamura K. Selective accumulation of PpIX and photodynamic effect after aminolevulinic acid treatment of human adenomyosis xenografts in nude mice. Fertil Steril 2008; 90 (04) 1523-1527
    CrossrefPubMedGoogle Scholar
  • 40 Chen YJ, Li HY, Huang CH. et al. Oestrogen-induced epithelial-mesenchymal transition of endometrial epithelial cells contributes to the development of adenomyosis. J Pathol 2010; 222 (03) 261-270
    CrossrefPubMedGoogle Scholar
  • 41 Zhou S, Yi T, Liu R. et al. Proteomics identification of annexin A2 as a key mediator in the metastasis and proangiogenesis of endometrial cells in human adenomyosis. Mol Cell Proteomics 2012; 11: M112
    CrossrefPubMedGoogle Scholar
  • 42 Koujyo T, Hatakeyama S, Yamada H. et al. Induction of endometriosis and adenomyosis by transvaginal pituitary transplantation in mice with and without natural killer cell activity. Am J Reprod Immunol 1998; 40 (06) 441-446
    CrossrefPubMedGoogle Scholar
  • 43 Mori T, Ohta Y, Nagasawa H. Ultrastructural changes in uterine myometrium of mice with experimentally-induced adenomyosis. Experientia 1984; 40 (12) 1385-1387
    CrossrefPubMedGoogle Scholar
  • 44 Mori T, Nagasawa H. Mechanisms of development of prolactin-induced adenomyosis in mice. Acta Anat (Basel) 1983; 116 (01) 46-54
    CrossrefPubMedGoogle Scholar
  • 45 Matsuda M, Sasabe H, Adachi Y, Suzuki T, Mori T. Increased invasion activity of endometrial stromal cells and elevated expression of matrix metalloproteinase messenger RNA in the uterine tissues of mice with experimentally induced adenomyosis. Am J Obstet Gynecol 2001; 185 (06) 1374-1380
    CrossrefPubMedGoogle Scholar
  • 46 Danilovich N, Roy I, Sairam MR. Emergence of uterine pathology during accelerated biological aging in FSH receptor-haploinsufficient mice. Endocrinology 2002; 143 (09) 3618-3627
    CrossrefPubMedGoogle Scholar
  • 47 Yamashita M, Matsuda M, Mori T. Increased expression of prolactin receptor mRNA in adenomyotic uterus in mice. Life Sci 1997; 60 (17) 1437-1446
    CrossrefPubMedGoogle Scholar
  • 48 Singtripop T, Mori T, Park MK, Sakamoto S, Kawashima S. Development of uterine adenomyosis after treatment with dopamine antagonists in mice. Life Sci 1991; 49 (03) 201-206
    CrossrefPubMedGoogle Scholar
  • 49 Kelly MA, Rubinstein M, Asa SL. et al. Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron 1997; 19 (01) 103-113
    CrossrefPubMedGoogle Scholar
  • 50 Huseby RA, Soares MJ, Talamantes F. Ectopic pituitary grafts in mice: hormone levels, effects on fertility, and the development of adenomyosis uteri, prolactinomas, and mammary carcinomas. Endocrinology 1985; 116 (04) 1440-1448
    CrossrefPubMedGoogle Scholar
  • 51 Lipschutz A, Iglesias R, Panasevich VI, Salinas S. Pathological changes induced in the uterus of mice with the prolonged administration of progesterone and 19-nor-contraceptives. Br J Cancer 1967; 21 (01) 160-165
    CrossrefPubMedGoogle Scholar
  • 52 Nagasawa H, Aoki M, Mori T. Effects of different schedules of progesterone treatment on mammary tumorigenesis and uterine adenomyosis in SHN virgin mice. Life Sci 1987; 40 (26) 2597-2602
    CrossrefPubMedGoogle Scholar
  • 53 Nagasawa H, Aoki M, Sakagami N, Ishida M. Medroxyprogesterone acetate enhances spontaneous mammary tumorigenesis and uterine adenomyosis in mice. Breast Cancer Res Treat 1988; 12 (01) 59-66
    CrossrefPubMedGoogle Scholar
  • 54 Ostrander PL, Mills KT, Bern HA. Long-term responses of the mouse uterus to neonatal diethylstilbestrol treatment and to later sex hormone exposure. J Natl Cancer Inst 1985; 74 (01) 121-135
    PubMedGoogle Scholar
  • 55 Bennett LM, McAllister KA, Malphurs J. et al. Mice heterozygous for a Brca1 or Brca2 mutation display distinct mammary gland and ovarian phenotypes in response to diethylstilbestrol. Cancer Res 2000; 60 (13) 3461-3469
    PubMedGoogle Scholar
  • 56 Walker BE. Tumors of female offspring of mice exposed prenatally to diethylstilbestrol. J Natl Cancer Inst 1984; 73 (01) 133-140
    PubMedGoogle Scholar
  • 57 Newbold RR, Jefferson WN, Padilla-Banks E. Long-term adverse effects of neonatal exposure to bisphenol A on the murine female reproductive tract. Reprod Toxicol 2007; 24 (02) 253-258
    CrossrefPubMedGoogle Scholar
  • 58 Bruner-Tran KL, Duleba AJ, Taylor HS, Osteen KG. Developmental toxicant exposure is associated with transgenerational adenomyosis in a murine model. Biol Reprod 2016; 95 (04) 73
    CrossrefPubMedGoogle Scholar
  • 59 Li Y, Zhang SF, Zou SE, Xia X, Bao L. Accumulation of nerve growth factor and its receptors in the uterus and dorsal root ganglia in a mouse model of adenomyosis. Reprod Biol Endocrinol 2011; 9: 30
    CrossrefPubMedGoogle Scholar
  • 60 Mehasseb MK, Bell SC, Habiba MA. The effects of tamoxifen and estradiol on myometrial differentiation and organization during early uterine development in the CD1 mouse. Reproduction 2009; 138 (02) 341-350
    CrossrefPubMedGoogle Scholar
  • 61 Mehasseb MK, Bell SC, Habiba MA. Neonatal administration of tamoxifen causes disruption of myometrial development but not adenomyosis in the C57/BL6J mouse. Reproduction 2010; 139 (06) 1067-1075
    CrossrefPubMedGoogle Scholar
  • 62 Green AR, Styles JA, Parrott EL. et al. Neonatal tamoxifen treatment of mice leads to adenomyosis but not uterine cancer. Exp Toxicol Pathol 2005; 56 (4-5): 255-263
    CrossrefPubMedGoogle Scholar
  • 63 Green AR, Edwards RE, Greaves P, White IN. Comparison of the effect of oestradiol, tamoxifen and raloxifene on nerve growth factor-alpha expression in specific neonatal mouse uterine cell types using laser capture microdissection. J Mol Endocrinol 2003; 30 (01) 1-11
    CrossrefPubMedGoogle Scholar
  • 64 Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 2009; 119 (06) 1438-1449
    CrossrefPubMedGoogle Scholar
  • 65 Shen M, Liu X, Zhang H, Guo SW. Transforming growth factor β1 signaling coincides with epithelial-mesenchymal transition and fibroblast-to-myofibroblast transdifferentiation in the development of adenomyosis in mice. Hum Reprod 2016; 31 (02) 355-369
    PubMedGoogle Scholar
  • 66 Jin Z, Liu H, Xu C. Estrogen degrades Scribble in endometrial epithelial cells through E3 ubiquitin ligase HECW1 in the development of diffuse adenomyosis. Biol Reprod 2020; 102 (02) 376-387
    PubMedGoogle Scholar
  • 67 Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 2009; 28 (1-2): 151-166
    CrossrefPubMedGoogle Scholar
  • 68 Arango NA, Szotek PP, Manganaro TF, Oliva E, Donahoe PK, Teixeira J. Conditional deletion of beta-catenin in the mesenchyme of the developing mouse uterus results in a switch to adipogenesis in the myometrium. Dev Biol 2005; 288 (01) 276-283
    CrossrefPubMedGoogle Scholar
  • 69 Kawahara R, Matsuda M, Mori T. Increase in the number of integrinbeta1-immunoreactive monocyte-lineage cells in experimentally-induced adenomyosis in mice. Life Sci 2003; 73 (07) 907-916
    CrossrefPubMedGoogle Scholar
  • 70 Marquardt RM, Kim TH, Shin JH, Jeong JW. Progesterone and estrogen signaling in the endometrium: What goes wrong in endometriosis?. Int J Mol Sci 2019; 20 (15) 20
    Google Scholar
  • 71 Che X, Wang J, He J, Guo X, Li T, Zhang X. The new application of mifepristone in the relief of adenomyosis-caused dysmenorrhea. Int J Med Sci 2020; 17 (02) 224-233
    CrossrefPubMedGoogle Scholar
  • 72 Singtripop T, Mori T, Sakamoto S, Sassa S, Park MK, Kawashima S. Suppression of the development of uterine adenomyosis by danazol treatment in mice. Life Sci 1992; 51 (14) 1119-1125
    CrossrefPubMedGoogle Scholar
  • 73 Otto C, Schkoldow J, Krahl E, Fuchs I, Ulbrich HF. Use of a murine endometriosis interna model for the characterization of compounds that effectively treat human endometriosis. Exp Ther Med 2012; 3 (03) 410-414
    CrossrefPubMedGoogle Scholar
  • 74 Zhang X, Yuan H, Deng L, Hu F, Ma J, Lin J. Evaluation of the efficacy of a danazol-loaded intrauterine contraceptive device on adenomyosis in an ICR mouse model. Hum Reprod 2008; 23 (09) 2024-2030
    CrossrefPubMedGoogle Scholar
  • 75 Selak V, Farquhar C, Prentice A, Singla A. Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst Rev 2001; (04) CD000068
    PubMedGoogle Scholar
  • 76 Guo S, Lu X, Gu R, Zhang D, Sun Y, Feng Y. Transcriptome analysis of endometrial tissues following GnRH agonist treatment in a mouse adenomyosis model. Drug Des Devel Ther 2017; 11: 695-704
    CrossrefPubMedGoogle Scholar
  • 77 Ferrero S, Evangelisti G, Barra F. Current and emerging treatment options for endometriosis. Expert Opin Pharmacother 2018; 19 (10) 1109-1125
    CrossrefPubMedGoogle Scholar
  • 78 Zhou YF, Matsuda M, Mori T, Sakamoto S, Mitamura T. Effects of mifepristone (RU486) treatment on the development of uterine adenomyosis induced by pituitary grafting in mice. Life Sci 2000; 67 (22) 2713-2720
    CrossrefPubMedGoogle Scholar
  • 79 Mori T, Kurata Y, Tabata Y, Niho N, Matsuda M, Zhou YF. Priming effects of novel nonsteroidal progesterone receptor modulators CP8816 and CP8863 on the development of adenomyosis in the mouse uterus. Life Sci 2002; 71 (05) 527-535
    CrossrefPubMedGoogle Scholar
  • 80 Kurata Y, Tabata Y, Shinei R. et al. Endocrinological properties of two novel nonsteroidal progesterone receptor modulators, CP8816 and CP8863. J Pharmacol Exp Ther 2005; 313 (02) 916-920
    CrossrefPubMedGoogle Scholar
  • 81 Nagasawa H, Noguchi Y, Mori T, Niki K, Namiki H. Suppression of normal and preneoplastic mammary growth and uterine adenomyosis with reduced growth hormone level in SHN mice given monosodium glutamate neonatally. Eur J Cancer Clin Oncol 1985; 21 (12) 1547-1551
    CrossrefPubMedGoogle Scholar
  • 82 Mao X, Wang Y, Carter AV, Zhen X, Guo SW. The retardation of myometrial infiltration, reduction of uterine contractility, and alleviation of generalized hyperalgesia in mice with induced adenomyosis by levo-tetrahydropalmatine (l-THP) and andrographolide. Reprod Sci 2011; 18 (10) 1025-1037
    CrossrefPubMedGoogle Scholar
  • 83 Chen Y, Zhu B, Zhang H, Liu X, Guo SW. Epigallocatechin-3-gallate reduces myometrial infiltration, uterine hyperactivity, and stress levels and alleviates generalized hyperalgesia in mice induced with adenomyosis. Reprod Sci 2013; 20 (12) 1478-1491
    CrossrefPubMedGoogle Scholar
  • 84 Chen Y, Zhu B, Zhang H, Ding D, Liu X, Guo SW. Possible loss of GABAergic inhibition in mice with induced adenomyosis and treatment with epigallocatechin-3-gallate attenuates the loss with improved hyperalgesia. Reprod Sci 2014; 21 (07) 869-882
    CrossrefPubMedGoogle Scholar
  • 85 Zhu B, Chen Y, Zhang H, Liu X, Guo SW. Resveratrol reduces myometrial infiltration, uterine hyperactivity, and stress levels and alleviates generalized hyperalgesia in mice with induced adenomyosis. Reprod Sci 2015; 22 (11) 1336-1349
    CrossrefPubMedGoogle Scholar
  • 86 Nie J, Liu X. Leonurine attenuates hyperalgesia in mice with induced adenomyosis. Med Sci Monit 2017; 23: 1701-1706
    CrossrefPubMedGoogle Scholar
  • 87 Feng T, Wei S, Wang Y. et al. Rhein ameliorates adenomyosis by inhibiting NF-κB and β-catenin signaling pathway. Biomed Pharmacother 2017; 94: 231-237
    CrossrefPubMedGoogle Scholar
  • 88 Liu X, Guo SW. Valproic acid alleviates generalized hyperalgesia in mice with induced adenomyosis. J Obstet Gynaecol Res 2011; 37 (07) 696-708
    CrossrefPubMedGoogle Scholar
  • 89 Jichan Nie, Xishi Liu, Guo SW. Promoter hypermethylation of progesterone receptor isoform B (PR-B) in adenomyosis and its rectification by a histone deacetylase inhibitor and a demethylation agent. Reprod Sci 2010; 17 (11) 995-1005
    CrossrefPubMedGoogle Scholar
  • 90 Mori T, Yamasaki S, Masui F, Matsuda M, Sasabe H, Zhou YF. Suppression of the development of experimentally induced uterine adenomyosis by a novel matrix metalloproteinase inhibitor, ONO-4817, in mice. Exp Biol Med (Maywood) 2001; 226 (05) 429-433
    CrossrefPubMedGoogle Scholar
  • 91 Zhou YF, Mori T, Kudo H, Asakai R, Sassa S, Sakamoto S. Effects of angiogenesis inhibitor TNP-470 on the development of uterine adenomyosis in mice. Fertil Steril 2003; 80 (Suppl. 02) 788-794
    CrossrefPubMedGoogle Scholar
  • 92 Zhou YF, Mori T, Nagasawa H, Nakayama T, Kubota T, Sakamoto S. Probucol, a hypocholesterolemic agent, prevents the development of uterine adenomyosis induced by pituitary grafting in mice. Anticancer Res 2004; 24 (04) 2209-2212
    PubMedGoogle Scholar
  • 93 Zhu B, Chen Y, Shen X, Liu X, Guo SW. Anti-platelet therapy holds promises in treating adenomyosis: experimental evidence. Reprod Biol Endocrinol 2016; 14 (01) 66
    CrossrefPubMedGoogle Scholar
  • 94 Sammour A, Pirwany I, Usubutun A, Arseneau J, Tulandi T. Correlations between extent and spread of adenomyosis and clinical symptoms. Gynecol Obstet Invest 2002; 54 (04) 213-216
    CrossrefPubMedGoogle Scholar
  • 95 Guo S-W, Habiba M. Improving the preclinical mouse efficacy studies of adenomyosis. In: Uterine Adenomyosis. Springer; 2016: 129-139
    Google Scholar
  • 96 Harada T, Khine YM, Kaponis A, Nikellis T, Decavalas G, Taniguchi F. The impact of adenomyosis on women's fertility. Obstet Gynecol Surv 2016; 71 (09) 557-568
    CrossrefPubMedGoogle Scholar
  • 97 Bruner-Tran KL, Osteen KG. Developmental exposure to TCDD reduces fertility and negatively affects pregnancy outcomes across multiple generations. Reprod Toxicol 2011; 31 (03) 344-350
    CrossrefPubMedGoogle Scholar
  • 98 Mehasseb MK, Panchal R, Taylor AH. et al. Estrogen and progesterone receptor isoform distribution through the menstrual cycle in uteri with and without adenomyosis. Fertil Steril 2011; 95: 2228-2235
    CrossrefPubMedGoogle Scholar
  • 99 Jeong JW, Lee HS, Franco HL. et al. beta-catenin mediates glandular formation and dysregulation of beta-catenin induces hyperplasia formation in the murine uterus. Oncogene 2009; 28 (01) 31-40
    CrossrefPubMedGoogle Scholar
  • 100 Guo S, Li Z, Yan L, Sun Y, Feng Y. GnRH agonist improves pregnancy outcome in mice with induced adenomyosis by restoring endometrial receptivity. Drug Des Devel Ther 2018; 12: 1621-1631
    CrossrefPubMedGoogle Scholar
  • 101 McEntee K, Nielsen SW. Tumours of the female genital tract. Bull World Health Organ 1976; 53 (2-3): 217-226
    PubMedGoogle Scholar
  • 102 Stöcklin-Gautschi NM, Guscetti F, Reichler IM, Geissbühler U, Braun SA, Arnold S. Identification of focal adenomyosis as a uterine lesion in two dogs. J Small Anim Pract 2001; 42 (08) 413-416
    CrossrefPubMedGoogle Scholar
  • 103 Gelberg HB, McEntee K. Pathology of the canine and feline uterine tube. Vet Pathol 1986; 23 (06) 770-775
    CrossrefPubMedGoogle Scholar
  • 104 Baldi A, Lanza A, Menicagli F, Signorile PG, Spugnini EP. Histological and immunohistochemical characterization of a case of endometriosis in a guinea pig (Cavia tschudii) . Case Rep Vet Med 2017; 2017: 4594510
    PubMedGoogle Scholar
  • 105 Meissner WA, Sommers SC, Sherman G. Endometrial hyperplasia, endometrial carcinoma, and endometriosis produced experimentally by estrogen. Cancer 1957; 10 (03) 500-509
    CrossrefPubMedGoogle Scholar
  • 106 Mori T, Kyokuwa M, Nagasawa H. Animal model of uterine adenomyosis: induction of the lesion in rats by ectopic pituitary isografting. Lab Anim Sci 1998; 48 (01) 64-68
    PubMedGoogle Scholar
  • 107 Sengupta P, Sharma A, Mazumdar G. et al. The possible role of fluoxetine in adenomyosis: an animal experiment with clinical correlations. J Clin Diagn Res 2013; 7 (07) 1530-1534
    PubMedGoogle Scholar